Biomimetic, synthetic HDL nanostructures for lymphoma.

Published

Journal Article

New therapies that challenge existing paradigms are needed for the treatment of cancer. We report a nanoparticle-enabled therapeutic approach to B-cell lymphoma using synthetic high density lipoprotein nanoparticles (HDL-NPs). HDL-NPs are synthesized using a gold nanoparticle template to control conjugate size and ensure a spherical shape. Like natural HDLs, biomimetic HDL-NPs target scavenger receptor type B-1, a high-affinity HDL receptor expressed by lymphoma cells. Functionally, compared with natural HDL, the gold NP template enables differential manipulation of cellular cholesterol flux in lymphoma cells, promoting cellular cholesterol efflux and limiting cholesterol delivery. This combination of scavenger receptor type B-1 binding and relative cholesterol starvation selectively induces apoptosis. HDL-NP treatment of mice bearing B-cell lymphoma xenografts selectively inhibits B-cell lymphoma growth. As such, HDL-NPs are biofunctional therapeutic agents, whose mechanism of action is enabled by the presence of a synthetic nanotemplate. HDL-NPs are active in B-cell lymphomas and potentially, other malignancies or diseases of pathologic cholesterol accumulation.

Full Text

Duke Authors

Cited Authors

  • Yang, S; Damiano, MG; Zhang, H; Tripathy, S; Luthi, AJ; Rink, JS; Ugolkov, AV; Singh, ATK; Dave, SS; Gordon, LI; Thaxton, CS

Published Date

  • February 12, 2013

Published In

Volume / Issue

  • 110 / 7

Start / End Page

  • 2511 - 2516

PubMed ID

  • 23345442

Pubmed Central ID

  • 23345442

Electronic International Standard Serial Number (EISSN)

  • 1091-6490

Digital Object Identifier (DOI)

  • 10.1073/pnas.1213657110

Language

  • eng

Conference Location

  • United States